

Org nr 556966-4955
November 13, 2025



Elicera Therapeutics announces that the Swedish Cancer Society has awarded Professor Magnus Essand at Uppsala University a grant of 7.5 million SEK for CAR T-cell research

Gothenburg, November 13, 2025 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies, armed with immune-activating properties via the company's commercially available iTANK platform, announces today that the Swedish Cancer Society has awarded Professor Magnus Essand at Uppsala University a grant of 7.5 million SEK for CAR T-cell research.

The grant is awarded to Professor Magnus Essand in his role as an employed academic researcher at Uppsala University and forms a natural part of the academic research activities. The funding, which spans three years, enables continued work for Essand's research group in the CAR T-cell field. With annual funding of 2.5 MSEK – an increase from the previous 1.75 MSEK – the group can now allocate greater resources to the research than before.

For further information, please contact:

Jamal El-Mosleh, CEO, Elicera Therapeutics AB (publ)

Phone: +46 (0) 703 31 90 51

jamal.elmosleh@elicera.com

Certified Advisor

DNB Carnegie Investment Bank (publ)

About the iTANK-platform

The iTANK technology platform has been developed for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: a very diverse set of tumor antigen targets and a very hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating bacterial protein (NAP). NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of CAR T-cells and importantly activating a parallel bystander immune response against the cancer via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK platform is used to enhance the company's own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. Proof-of-concept data was published in Nature Biomedical Engineering in April 2022. The publication, titled "CAR T cells expressing a bacterial virulence factor triggers potent bystander antitumor responses in solid cancers" (DOI number: 10.1038/s41551-022-00875-5) can be found here:

<https://www.nature.com/articles/s41551-022-00875-5>. More information about iTANK platform is available here: <https://www.elicera.com/technology>

About Elicera Therapeutics AB

Elicera Therapeutics AB (publ) has developed the patented gene technology platform iTANK that enables the arming of new and existing CAR T-cell therapies targeting aggressive and relapsing cancer forms. Elicera Therapeutics thereby addresses a well-defined and vast market. The company's CAR T-cell therapies have shown a potent effect toward solid tumors which are recognized as particularly difficult to treat and constitute the majority of cancer cases. The company addresses a global multibillion market in cell therapy through its offering of non-exclusive licensing of the iTANK-platform to companies in the pharmaceutical industry. Elicera Therapeutics has four internal development projects in immune therapy that separately have the potential to generate substantial value through exclusive out-licensing agreements. The company's share is traded on Nasdaq First North Growth Market. For additional information, visit www.elicera.com.